After consolidating his position as one of the most successful billionaires in the pharmaceutical industry (with assets of more than US$3.8 billion), Pablo Legorreta continues to do what he knows: invest in patents under development to extract their value once new products are on the market. Between mid-2021 to 2022, Royalty Pharma had transactions for US$2.5 billion, so the company Legorreta founded continues to lead the early- or late-stage pharma investment niche.
PUBLICIDAD
Select a country
